非肥胖中老年人群 TG/HDL-C 对代谢相关脂肪性肝病的预测价值

宋颖 ,  刘奕婷 ,  王巍

中国卫生统计 ›› 2026, Vol. 43 ›› Issue (4) : 601 -604,610.

PDF (1112KB)
中国卫生统计 ›› 2026, Vol. 43 ›› Issue (4) : 601 -604,610. DOI: 10.11783/j.issn.1002-3674.2026.04.023
应用研究

非肥胖中老年人群 TG/HDL-C 对代谢相关脂肪性肝病的预测价值

作者信息 +

Author information +
文章历史 +
PDF (1138K)

摘要

目的 探讨非肥胖中老年人群甘油三酯(triglycerides,TG)/高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)与代谢相关脂肪性肝病(metabolic dysfunction-associated fatty liver disease,MAFLD)的关联。方法 利用中国医科大学附属第一医院45岁及以上人群体检数据进行横断面研究。采用多因素logistic回归分析探究TG/HDL-C与MAFLD的关系。采用限制性立方样条模型探索TG/HDL-C与MAFLD患病风险的非线性关系,通过阈值效应确定拐点。采用受试者工作特征曲线评估TG/HDL-C的预测价值。结果 调查17252人,检出MAFLD 8122例,检出率为47.08%。多因素 logistic 回归分析结果显示,在校正潜在的混杂因素后,TG/HDL-C与 MAFLD呈正相关(OR=1.921,95%CI:1.826~2.02,P<0.001)。随着TG/HDL-C四分位数分组的升高,MAFLD风险逐步增加(P趋势性值<0.001)。限制性立方样条分析结果显示TG/HDL-C与MAFLD之间存在非线性关系,拐点为2.546,该拐点两侧的OR值(95%CI)分别为2.96(2.734~3.206),1.17(1.068~1.281)。TG/HDL-C预测MAFLD风险的ROC曲线下面积为0.759,95%CI为0.751~0.766。结论 TG/HDL-C与非肥胖中老年人群MAFLD呈非线性正相关,能有效预测MAFLD患病风险。

关键词

甘油三酯 / 高密度脂蛋白胆固醇 / 代谢相关脂肪性肝病

Key words

引用本文

引用格式 ▾
宋颖,刘奕婷,王巍. 非肥胖中老年人群 TG/HDL-C 对代谢相关脂肪性肝病的预测价值[J]. 中国卫生统计, 2026, 43(4): 601-604,610 DOI:10.11783/j.issn.1002-3674.2026.04.023

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Lou TW, Yang RX, Fan JG. The global burden of fatty liver disease: the major impact of China [J].Hepatobiliary Surgery and Nutrition, 2024, 13(1): 119-123.

[2]

中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].中华肝脏病杂志, 2024, 32(5): 418-434.

[3]

Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia [J].Journal of Hepatology, 2017, 67(4): 862-873.

[4]

Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease [J].Cell, 2021, 184(10): 2537-2564.

[5]

Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non—obese or lean non—alcoholic fatty liver disease: a systematic review and meta—analysis [J].Lancet Gastroenterol Hepatol, 2020, 5(8): 739-752.

[6]

Cheng W, Zhuang J, Chen S. Dyslipidemia and the Prevalence of Hypertension: A Cross—Sectional Study Based on Chinese Adults Without Type 2 Diabetes Mellitus [J].Frontiers in Cardiovascular Medicine, 2022, 9: 938363.

[7]

Kosmas CE, Rodriguez Polanco S, Bousvarou MD, et al. The Triglyceride/High—Density Lipoprotein Cholesterol (TG/HDL—C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease [J].Diagnostics, 2023, 13(5): 929.

[8]

Che B, Zhong C, Zhang R, et al. Triglyceride—glucose index and triglyceride to high—density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data [J].Cardiovascular Diabetology, 2023, 22(1): 34.

[9]

Liu Z, He H, Dai Y, et al. Comparison of the diagnostic value between triglyceride—glucose index and triglyceride to high—density lipoprotein cholesterol ratio in metabolic—associated fatty liver disease patients: a retrospective cross—sectional study [J].Lipids in Health and Disease, 2022, 21(1): 55.

[10]

孟雪,王慧文. 甘油三酯/高密度脂蛋白胆固醇比值与高血压的相关性研究[J].中国卫生统计, 2025,42(4): 546-550.

[11]

Charatcharoenwitthaya P, Kuljiratitikal K, Aksornchanya O, et al. Moderate—Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial [J].Clinical and Translational Gastroenterology, 2021, 12(3): e00316.

[12]

Zhang D, Niu S, Ma Y, et al. Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let—7/SERCA2b Axis in High—Fat Diet—Induced Non—Alcoholic Fatty Liver Disease Mice [J].Frontiers in Pharmacology, 2022, 12: 770652.

[13]

Gong R, Luo G, Wang M, et al. Associations between TG/HDL ratio and insulin resistance in the US population: a cross—sectional study [J].Endocrine Connections, 2021, 10(11): 1502-1512.

[14]

Sakurai Y, Kubota N, Yamauchi T, et al. Role of Insulin Resistance in MAFLD [J].International Journal of Molecular Sciences, 2021, 22(8): 4156.

[15]

Cobbina E, Akhlaghi F. Non—alcoholic fatty liver disease (NAFLD) — pathogenesis, classification, and effect on drug metabolizing enzymes and transporters [J].Drug Metabolism Reviews, 2017, 49(2): 197-211.

[16]

Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction—associated fatty liver disease [J]. Trends in Endocrinology & Metabolism,2021, 32(7): 500-514.

[17]

Huang JF, Tsai PC, Yeh ML, et al. Risk stratification of non—alcoholic fatty liver disease across body mass index in a community basis [J].Journal of the Formosan Medical Association, 2020, 119(1): 89-96.

[18]

Peterson JM, Alcala M, Calderon DM, et al. Short—term vitamin E treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice [J].PLos One, 2017, 12(10): e0186579.

[19]

Benhamed F, Denechaud PD, Lemoine M, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans [J].Journal of Clinical Investigation, 2012, 122(6): 2176-2194.

[20]

Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism [J].Obesity Reviews, 2013, 14(12): 939-949.

[21]

Lucero D, Miksztowicz V, Macri V, et al. Overproduction of altered VLDL in an insulin—resistance rat model: Influence of SREBP—1c and PPAR—α [J].Clínica e Investigación en Arteriosclerosis, 2015, 27(4): 167-174.

[22]

Tilg H, Adolph T E, Dudek M, et al. Non—alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity [J].Nature Metabolism, 2021, 3(12): 1596-1607.

AI Summary AI Mindmap
PDF (1112KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉